GleamWall
中文EN

ACXP Acurx Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1736243 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.7%
TTM EPS YoY76.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-147.5%
ROA-98.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$1.83M$5.40M
SG&A expense$6.26M$8.72M
Operating income-$8.09M-$14.12M
Net income-$7.97M-$14.10M
EPS (basic)-5.32-17.45
EPS (diluted)-5.32-17.45
Weighted avg. shares (diluted)1.50M808,168
Balance sheet
Cash & equivalents$7.56M$3.71M
Current assets—$3.86M
Total assets$7.69M$3.86M
Current liabilities$2.42M$3.24M
Total liabilities$2.42M$3.24M
Shareholders' equity$5.27M$615,121
Shares outstanding2.35M851,534
Cash flow statement
Operating cash flow-$6.79M-$10.38M
Financing cash flow$10.64M$6.62M
Stock-based compensation$1.25M$2.60M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.